InvestWiser

Oncopeptides AB

ONCONasdaq StockholmHealthcareMarket value 725 m SEK
1.68SEK −2.9%
last day · Price as of 18 November 2026

The answer first

Does Oncopeptides beat the market?

No, Oncopeptides has not beaten the market over the last year.

Oncopeptides−65.1%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 5% of Nordic stocks

    • Quality28
    • Value2
    • Trend37

    No. 175 of 195 in healthcare

Max for seven days

Follow Oncopeptides with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Oncopeptides

From today, at a price of 1.68 SEK. Write why you follow Oncopeptides, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Oncopeptides

Your first answer is free, no account needed.

Do you own Oncopeptides, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Oncopeptides and a few more. Free, no card.

Past year against the exchange and Super Stock
Oncopeptides−65.1%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Oncopeptides has fallen 65.1% over the past year, including dividends.
  • Overall, Oncopeptides ranks better than 5% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 97.4%. The price is 98.7% below its peak now.

What do analysts think of Oncopeptides?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

5

Quality, value and trend together. Better than 5% of Nordic stocks.

No. 175 of 195 in healthcare

Quality28
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 160 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity−8.45
  • Asset turnoverSales divided by everything the company owns0.59
  • Return on equityProfit divided by equity−287.9%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 182 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equitynegative earnings
  • P/SPrice divided by sales5.9
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend37
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 90 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+0.3%
  • 6 months−2.4%
  • 9 months+4.8%
  • 12 months−65.1%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−2.7%
3 years, per year
−26.9%
5 years, per year
−12.7%
Year to date
−62.9%
Largest fall, 3 years
−97.4%
From a peak to the bottom
From the peak now
−98.7%
How far the price is from the peak
Volatility, 1 year
101.4%
How much the price swings over a year
Beta, 1 year
1.20
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Oncopeptides

5 funds we follow own Oncopeptides. The share is how much of the fund the stock makes up.

  • Sweden5

From the funds' latest known holdings.

About Oncopeptides

Oncopeptides AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 71 employees.

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.

See the full analysis of Oncopeptides.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market